Identification and preclinical pharmacology of the γ -secretase modulator BMS-869780

International Journal of Alzheimer's Disease

Volumn 2014, Issue , 2014, Pages

  Toyn, Jeremy H ^a   Thompson, Lorin A ^a   Lentz, Kimberley A ^a   Meredith, Jere E ^a   Burton, Catherine R ^a   Sankaranararyanan, Sethu ^a   Guss, Valerie ^a   Hall, Tracey ^a,b   Iben, Lawrence G ^a   Krause, Carol M ^a   Krause, Rudy ^a   Lin, Xu Alan ^a   Pierdomenico, Maria ^a   Polson, Craig ^a   Robertson, Alan S ^a   Denton, R Rex ^a   Grace, James E ^a   Morrison, John ^a   Raybon, Joseph ^a   Zhuo, Xiaoliang ^a   Snow, Kimberly ^a   Padmanabha, Ramesh ^a   Agler, Michele ^a,c   Esposito, Kim ^a   Harden, David ^a   Prack, Margaret ^a   Varma, Sam ^a,d   Wong, Victoria ^a,e   Zhu, Yingjie ^a,f   Zvyaga, Tatyana ^a   Gerritz, Samuel ^a   Marcin, Lawrence R ^a   Higgins, Mendi A ^a   Shi, Jianliang ^a   Wei, Cong ^a,e   Cantone, Joseph L ^a   Drexler, Dieter M ^a   Macor, John E ^a   Olson, Richard E ^a   Ahlijanian, Michael K ^a   Albright, Charles F ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d Stratford High School   (United States)

^e PFIZER INC   (United States)

^f Arvinas Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BMS 869780; NOTCH RECEPTOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EMBRYO; FEMALE; HAPLORHINI; HUMAN; IN VITRO STUDY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHARMACOLOGY; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84904659446     PISSN: 20908024     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2014/431858     Document Type: Article

References (80)

1. Wimo A., Prince M., The global economic impact of dementia. Alzheimer's Disease International World Alzheimer Report 2010 2010
2. Prince M., Bryce R., Ferri C., The benefits of early diagnosis and intervention. Alzheimer's Disease International World Alzheimer Report 2011 2011
3. Findeis M. A., The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacology & Therapeutics 2007 116 2 266 286 2-s2.0-34548812551 10.1016/j.pharmthera.2007.06.006 (Pubitemid 47451506)
4. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 2-s2.0-0037135111 10.1126/science.1072994 (Pubitemid 34790756)
5. Karran E., Mercken M., de Strooper B., The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery 2011 10 9 698 712 2-s2.0-80052266213 10.1038/nrd3505
6. Haass C., Take five-BACE and the γ -secretase quartet conduct Alzheimer's amyloid β -peptide generation. The EMBO Journal 2004 23 3 483 488 2-s2.0-1442264828 10.1038/sj.emboj.7600061 (Pubitemid 38282380)
7. Toyn J. H., Ahlijanian M. K., Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid- β Alzheimer's Research & Therapy 2014 6, article 14
8. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T., Selkoe D. J., Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ -secretase activity. Nature 1999 398 6727 513 517 2-s2.0-0033535553 10.1038/19077 (Pubitemid 29177490)
9. Lundqvist J., Näslund J., γ -Secretase: a complex target for Alzheimer's disease. Current Opinion in Pharmacology 2007 7 112 118 10.1016/B978-0-12-394816-8.00004-0 (Pubitemid 46238041)
10. Lazarov V. K., Fraering P. C., Ye W., Wolfe M. S., Selkoe D. J., Li H., Electron microscopic structure of purified, active γ -secretase reveals an aqueous intramembrane chamber and two pores. Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 6889 6894 2-s2.0-33646483640 10.1073/pnas.0602321103
11. Osenkowski P., Li H., Ye W., Li D., Aeschbach L., Fraering P. C., Wolfe M. S., Selkoe D. J., Li H., Cryoelectron microscopy structure of purified γ -secretase at 12 Å resolution. Journal of Molecular Biology 2009 385 2 642 652 2-s2.0-58149094674 10.1016/j.jmb.2008.10.078
12. Renzi F., Zhang X., Rice W. J., Torres-Arancivia C., Gomez-Llorente Y., Diaz R., Ahn K., Yu C., Li Y.-M., Sisodia S. S., Ubarretxena-Belandia I., Structure of γ -secretase and its trimeric pre-activation intermediate by single-particle electron microscopy. The Journal of Biological Chemistry 2011 286 24 21440 21449 2-s2.0-79958718948 10.1074/jbc.M110.193326
13. Sato C., Morohashi Y., Tomita T., Iwatsubo T., Structure of the catalytic pore of γ -secretase probed by the accessibility of substituted cysteines. The Journal of Neuroscience 2006 26 46 12081 12088 2-s2.0-33751087756 10.1523/JNEUROSCI.3614-06.2006 (Pubitemid 44772118)
14. Sato T., Diehl T. S., Narayanan S., Funamoto S., Ihara Y., De Strooper B., Steiner H., Haass C., Wolfe M. S., Active γ -secretase complexes contain only one of each component. The Journal of Biological Chemistry 2007 282 47 33985 33993 2-s2.0-36349024875 10.1074/jbc.M705248200 (Pubitemid 350159441)
15. Li X., Dang S., Yan C., Gong X., Wang J., Shi Y., Structure of a presenilin family intramembrane aspartate protease. Nature 2013 493 7430 56 61 2-s2.0-84871725890 10.1038/nature11801
16. Haapasalo A., Kovacs D. M., The many substrates of presenilin/ γ -secretase. Journal of Alzheimer's Disease 2011 25 1 3 28 2-s2.0-79959636033 10.3233/JAD-2011-101065
17. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., Jacobs R. T., Zacco A., Greenberg B., Ciaccio P. J., Modulation of Notch processing by γ -secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicological Sciences 2004 82 1 341 358 2-s2.0-8444247084 10.1093/toxsci/kfh254 (Pubitemid 39485346)
18. Wong G. T., Manfra D., Poulet F. M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J. S., Lee H.-J. J., Zhang L., Higgins G. A., Parker E. M., Chronic treatment with the γ -secretase inhibitor LY-411,575 inhibits γ -amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. The Journal of Biological Chemistry 2004 279 13 12876 12882 2-s2.0-11144355129 10.1074/jbc.M311652200 (Pubitemid 38445862)
19. Albright C. F., Dockens R., Meredith J. E. Jr., Olson R. E., Slemmon R., Lentz K. A., Wang J.-S., Denton R. R., Pilcher G., Rhyne P. W., Raybon J. J., Barten D. M., Burton C., Toyn J. H., Sankaranarayanan S., Polson C., Guss V., White R., Simutis F., Sanderson T., Gillman K. W., Starrett J. E., Bronson J., Sverdlov O., Huang S.-P., Castaneda L., Feldman H., Coric V., Zaczek R., Macor J. E., Houston J., Berman R. M., Tong G., Pharmacodynamics of selective inhibition of γ -secretase by avagacestat. Journal of Pharmacology and Experimental Therapeutics 2013 344 3 686 695 2-s2.0-84874426209 10.1124/jpet.112.199356
20. Crump C. J., Fish B. A., Castro S. V., Chau D.-M., Gertsik N., Ahn K., Stiff C., Pozdnyakov N., Bales K. R., Johnson D. S., Li Y.-M., Piperidine acetic acid based γ -secretase modulators directly bind to presenilin-1. ACS Chemical Neuroscience 2011 2 12 705 710 2-s2.0-82455172862 10.1021/cn200098p
21. Ebke A., Luebbers T., Fukumori A., Shirotani K., Haass C., Baumann K., Steiner H., Novel γ -secretase enzyme modulators directly target presenilin protein. The Journal of Biological Chemistry 2011 286 43 37181 37186 2-s2.0-80054801471 10.1074/jbc.C111.276972
22. Ohki Y., Higo T., Uemura K., Shimada N., Osawa S., Berezovska O., Yokoshima S., Fukuyama T., Tomita T., Iwatsubo T., Phenylpiperidine-type γ -secretase modulators target the transmembrane domain 1 of presenilin 1. The EMBO Journal 2011 30 23 4815 4824 2-s2.0-82455167920 10.1038/emboj.2011.372
23. Jumpertz T., Rennhack A., Ness J., Baches S., Pietrzik C. U., Bulic B., Weggen S., Presenilin is the molecular target of acidic γ -secretase modulators in living cells. PLoS ONE 2012 7 1, article e30484 2-s2.0-84855420378 10.1371/journal.pone.0030484
24. Pozdnyakov N., Murrey H. E., Crump C. J., Pettersson M., Ballard T. E., Am Ende C. W., Ahn K., Li Y.-M., Bales K. R., Johnson D. S., γ -Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. The Journal of Biological Chemistry 2013 288 14 9710 9720 2-s2.0-84875996404 10.1074/jbc.M112.398602
25. Tate B., McKee T. D., Loureiro R. M. B., Modulation of gamma-secretase for the treatment of Alzheimer's disease. International Journal of Alzheimer's Disease 2012 2012 10 210756 10.1155/2012/210756
26. Okochi M., Fukumori A., Jiang J., Itoh N., Kimura R., Steiner H., Haass C., Tagami S., Takeda M., Secretion of the Notch-1 A β -like peptide during Notch signaling. The Journal of Biological Chemistry 2006 281 12 7890 7898 2-s2.0-33646353694 10.1074/jbc.M513250200 (Pubitemid 43847405)
27. Okochi M., Steiner H., Fukumori A., Tanii H., Tomita T., Tanaka T., Iwatsubo T., Kudo T., Takeda M., Haass C., Presenilins mediate a dual intramembranous γ -secretase cleavage of Notch-1. The EMBO Journal 2002 21 20 5408 5416 2-s2.0-18644367748 10.1093/emboj/cdf541 (Pubitemid 35231020)
28. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., Findlay K. A., Smith T. E., Murphy M. P., Bulter T., Kang D. E., Marquez-Sterling N., Golde T. E., Koo E. H., A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity. Nature 2001 414 6860 212 216 2-s2.0-0035829592 10.1038/35102591 (Pubitemid 33051236)
29. Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., Ihara Y., γ -Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of β -carboxyl terminal fragment. The Journal of Neuroscience 2009 29 41 13042 13052 2-s2.0-70350451482 10.1523/JNEUROSCI.2362-09.2009
30. Takami M., Funamoto S., γ -Secretase-dependent proteolysis of transmembrane domain of amyloid precursor protein: successive tri-and tetrapeptide release in amyloid β -protein production. International Journal of Alzheimer's Disease 2012 2012 7 2-s2.0-84872812991 10.1155/2012/591392 591392
31. Sato T., Dohmae N., Qi Y., Kakuda N., Misonou H., Mitsumori R., Maruyama H., Koo E. H., Haass C., Takio K., Morishima-Kawashima M., Ishiura S., Ihara Y., Potential link between amyloid β -protein 42 and C-terminal fragment γ 49-99 of β -amyloid precursor protein. The Journal of Biological Chemistry 2003 278 27 24294 20301 2-s2.0-0041589353 10.1074/jbc.M211161200 (Pubitemid 37548579)
32. Chávez-Gutiérrez L., Bammens L., Benilova I., The mechanism of γ -secretase dysfunction in Alzheimer's disease. The EMBO Journal 2012 31 10 2261 2274 10.1038/emboj.2012.79
33. Eriksen J. L., Sagi S. A., Smith T. E., Weggen S., Das P., McLendon D. C., Ozols V. V., Jessing K. W., Zavitz K. H., Koo E. H., Golde T. E., NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo. The Journal of Clinical Investigation 2003 112 3 440 449 2-s2.0-0042888943 10.1172/JCI200318162 (Pubitemid 38063773)
34. Kukar T., Prescott S., Eriksen J. L., Holloway V., Murphy M. P., Koo E. H., Golde T. E., Nicolle M. M., Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neuroscience 2007 8, article 54 2-s2.0-34547884277 10.1186/1471-2202-8-54 (Pubitemid 47261345)
35. Galasko D. R., Graff-Radford N., May S., Hendrix S., Cottrell B. A., Sagi S. A., Mather G., Laughlin M., Zavitz K. H., Swabb E., Golde T. E., Murphy M. P., Koo E. H., Safety, tolerability, pharmacokinetics, and A β levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Disease & Associated Disorders 2007 21 4 292 299 2-s2.0-37349104196 10.1097/WAD.0b013e31815d1048 (Pubitemid 350307433)
36. Nakano-Ito K., Fujikawa Y., Hihara T., Shinyo H., Kotani S., Suganuma A., Aoki T., Tsukidate K., E2012-induced cataract and its predictive biomarkers. Toxicological Sciences 2014 137 1 249 258
37. Yu Y., Logovinsky V., Schuck E., Kaplow J., Chang M. K., Miyagawa T., Wong N., Ferry J., Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ -secretase modulator, E2212, in healthy human subjects. The Journal of Clinical Pharmacology 2014 54 5 528 536 10.1002/jcph.249
38. Caldwell J. P., Bennett C. E., McCracken T. M., Mazzola R. D., Bara T., Buevich A., Burnett D. A., Chu I., Cohen-Williams M., Josein H., Hyde L., Lee J., McKittrick B., Song L., Terracina G., Voigt J., Zhang L., Zhu Z., Iminoheterocycles as γ -secretase modulators. Bioorganic & Medicinal Chemistry Letters 2010 20 18 5380 5384 2-s2.0-77956176235 10.1016/j.bmcl.2010. 07.121
39. Kounnas M. Z., Danks A. M., Cheng S., Tyree C., Ackerman E., Zhang X., Ahn K., Nguyen P., Comer D., Mao L., Yu C., Pleynet D., Digregorio P. J., Velicelebi G., Stauderman K. A., Comer W. T., Mobley W. C., Li Y.-M., Sisodia S. S., Tanzi R. E., Wagner S. L., Modulation of γ -secretase reduces β -amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010 67 5 769 780 2-s2.0-77956311201 10.1016/j.neuron.2010.08.018
40. Stanton M. G., Hubbs J., Sloman D., Hamblett C., Andrade P., Angagaw M., Bi G., Black R. M., Crispino J., Cruz J. C., Fan E., Farris G., Hughes B. L., Kenific C. M., Middleton R. E., Nikov G., Sajonz P., Shah S., Shomer N., Szewczak A. A., Tanga F., Tudge M. T., Shearman M., Munoz B., Fluorinated piperidine acetic acids as γ -secretase modulators. Bioorganic & Medicinal Chemistry Letters 2010 20 2 755 758 2-s2.0-72249100345 10.1016/j.bmcl.2009.11.034
41. Hawkins J., Harrison D. C., Ahmed S., Davis R. P., Chapman T., Marshall I., Smith B., Mead T. L., Medhurst A., Giblin G. M. P., Hall A., Gonzalez M. I., Richardson J., Hussain I., Dynamics of A β 42 reduction in plasma, CSF and brain of rats treated with the γ -secretase modulator, GSM-10h. Neurodegenerative Diseases 2011 8 6 455 464 2-s2.0-79960566232 10.1159/000324511
42. Hussain I., Harrison D. C., Hawkins J., Chapman T., Marshall I., Facci L., Ahmed S., Brackenborough K., Skaper S. D., Mead T. L., Smith B. B., Giblin G. M. P., Hall A., Gonzalez M. I., Richardson J. C., TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ -secretase modulation and amyloid- β 42 lowering by GSM-10h. Neurodegenerative Diseases 2011 8 1-2 15 24 2-s2.0-78650179098 10.1159/000313903
43. Li T., Huang Y., Jin S., Ye L., Rong N., Yang X., Ding Y., Cheng Z., Zhang J., Wan Z., Harrison D. C., Hussain I., Hall A., Lee D. H. S., Lau L.-F., Matsuoka Y., γ -Secretase modulators do not induce A β -rebound and accumulation of β -C-terminal fragment. Journal of Neurochemistry 2012 121 2 277 286 2-s2.0-84862792622 10.1111/j.1471-4159.2011.07560.x
44. Peng H., Talreja T., Xin Z., Cuervo J. H., Kumaravel G., Humora M. J., Xu L., Rohde E., Gan L., Jung M.-Y., Shackett M. N., Chollate S., Dunah A. W., Snodgrass-Belt P. A., Arnold H. M., Taveras A. G., Rhodes K. J., Scannevin R. H., Discovery of BIIB042, a potent, selective, and orally bioavailable γ -secretase modulator. ACS Medicinal Chemistry Letters 2011 2 10 786 791 2-s2.0-80054749437 10.1021/ml200175q
45. van Broeck B., Chen J.-M., Tréton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M., Rowley A., Chronic treatment with a novel γ -secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. British Journal of Pharmacology 2011 163 2 375 389 2-s2.0-79954480259 10.1111/j.1476-5381.2011.01207.x
46. Wan Z., Hall A., Sang Y., Xiang J.-N., Yang E., Smith B., Harrison D. C., Yang G., Yu H., Price H. S., Wang J., Hawkins J., Lau L.-F., Johnson M. R., Li T., Zhao W., Mitchell W. L., Su X., Zhang X., Zhou Y., Jin Y., Tong Z., Cheng Z., Hussain I., Elliott J. D., Matsuoka Y., Pyridine-derived γ -secretase modulators. Bioorganic & Medicinal Chemistry Letters 2011 21 16 4832 4835 2-s2.0-79960921944 10.1016/j.bmcl.2011.06.042
47. Borgegard T., Juréus A., Olsson F., Rosqvist S., Sabirsh A., Rotticci D., Paulsen K., Klintenberg R., Yan H., Waldman M., Stromberg K., Nord J., Johansson J., Regner A., Parpal S., Malinowsky D., Radesater A.-C., Li T., Singh R., Eriksson H., Lundkvist J., First and second generation γ -secretase modulators (GSMs) modulate amyloid- β (A β) peptide production through different mechanisms. The Journal of Biological Chemistry 2012 287 15 11810 11819 2-s2.0-84859496092 10.1074/jbc.M111.305227
48. Mitani Y., Yarimizu J., Saita K., Uchino H., Akashiba H., Shitaka Y., Ni K., Matsuoka N., Differential effects between γ -secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. The Journal of Neuroscience 2012 32 6 2037 2050 2-s2.0-84857020179 10.1523/JNEUROSCI.4264-11.2012
49. Sun Z.-Y., Asberom T., Bara T., Bennett C., Burnett D., Chu I., Clader J., Cohen-Williams M., Cole D., Czarniecki M., Durkin J., Gallo G., Greenlee W., Josien H., Huang X., Hyde L., Jones N., Kazakevich I., Li H., Liu X., Lee J., MacCoss M., Mandal M. B., McCracken T., Nomeir A., Mazzola R., Palani A., Parker E. M., Pissarnitski D. A., Qin J., Song L., Terracina G., Vicarel M., Voigt J., Xu R., Zhang L., Zhang Q., Zhao Z., Zhu X., Zhu Z., Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ -secretase modulators in vivo. Journal of Medicinal Chemistry 2012 55 1 489 502 2-s2.0-84862909040 10.1021/jm201407j
50. Huang Y., Li T., Eatherton A., Mitchell W. L., Rong N., Ye L., Yang X.-J., Jin S., Ding Y., Zhang J., Li Y., Wu Y., Jin Y., Sang Y., Cheng Z., Browne E. R., Harrison D. C., Hussain I., Wan Z., Hall A., Lau L.-F., Matsuoka Y., Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ -secretase modulators reduced amyloidogenic A β peptides in vivo. Neuropharmacology 2013 70 278 286 2-s2.0-84876965841 10.1016/j.neuropharm.2013. 02.003
51. Loureiro R. M., Dumin J. A., McKee T. D., Austin W. F., Fuller N. O., Hubbs J. L., Shen R., Jonker J., Ives J., Bronk B. S., Tate B., Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models. Alzheimer's Research & Therapy 2013 5 2, article 19 2-s2.0-84876164001 10.1186/alzrt173
52. Rogers K., Felsenstein K. M., Hrdlicka L., Tu Z., Albayya F., Lee W., Hopp S., Miller M.-J., Spaulding D., Yang Z., Hodgdon H., Nolan S., Wen M., Costa D., Blain J.-F., Freeman E., De Strooper B., Vulsteke V., Scrocchi L., Zetterberg H., Portelius E., Hutter-Paier B., Havas D., Ahlijanian M., Flood D., Leventhal L., Shapiro G., Patzke H., Chesworth R., Koenig G., Modulation of γ -secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Molecular Neurodegeneration 2012 7 1, article 61 2-s2.0-84871151505 10.1186/1750-1326-7-61
53. Mitani Y., Yarimizu J., Akashiba H., Shitaka Y., Ni K., Matsuoka N., Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A β 42 without affecting other A β pools. Journal of Neurochemistry 2013 125 3 465 472 2-s2.0-84876665764 10.1111/jnc.12125
54. Marcin L. R., Thompson L. A. III, Boy K. M., Bicyclic compounds for the reduction of beta-amyloid production. Bristol-Myers Squibb 2010 US20110015175, WO2010083141
55. Marcin L. R., Higgins M. A., Lentz K. A., Bicyclic triazoles as modulators of γ -secretase for the treatment of Alzheimer's disease. Proceedings of the 243rd ACS National Meeting & Exposition March 2012 San Diego, Calif, USA
56. Barten D. M., Guss V. L., Corsa A., Loo A., Hansel S. B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B. J., Polson C. T., Wang J., Roberts S. B., Hendrick J. P., Anderson J. J., Loy J. K., Denton R., Verdoorn T. A., Smith D. W., Felsenstein K. M., Dynamics of β -amyloid reductions in brain, cerebrospinal fluid, and plasma of β -amyloid precursor protein transgenic mice treated with a γ -secretase inhibitor. Journal of Pharmacology and Experimental Therapeutics 2005 312 2 635 643 2-s2.0-19944430290 10.1124/jpet.104.075408 (Pubitemid 40189561)
57. Prasad C. V. C., Zheng M., Vig S., Bergstrom C., Smith D. W., Gao Q., Yeola S., Polson C. T., Corsa J. A., Guss V. L., Loo A., Wang J., Sleczka B. G., Dangler C., Robertson B. J., Hendrick J. P., Roberts S. B., Barten D. M., Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)- N -((S,Z)-3-methyl-4-oxo-4,5-dihydro-3 H -benzo[ d ][1,2]diazepin-5-yl)propanamide (BMS-433796): A γ -secretase inhibitor with A β lowering activity in a transgenic mouse model of Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters 2007 17 14 4006 4011 2-s2.0-34250365682 10.1016/j.bmcl.2007. 04.082 (Pubitemid 46920926)
58. Gilligan P. J., Sulfonamide bicyclic compounds. Bristol-Myers Squibb 2005 US20067144894, WO2006034480
59. Gillman K., Starrett J. E. Jr., Parker M. F., Xie K., Bronson J. J., Marcin L. R., McElhone K. E., Bergstrom C. P., Mate R. A., Williams R., Meredith J. E., Burton C. R., Barten D. M., Toyn J. H., Roberts S. B., Lentz K. A., Houston J. G., Zaczek R., Albright C. F., Decicco C. P., MacOr J. E., Olson R. E., Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ -secretase inhibitor. ACS Medicinal Chemistry Letters 2010 1 3 120 124 2-s2.0-77954122667 10.1021/ml1000239
60. Herreman A., Hartmann D., Annaert W., Saftig P., Craessaerts K., Serneels L., Umans L., Schrijvers V., Checler F., Vanderstichele H., Baekelandt V., Dressel R., Cupers P., Huylebroeck D., Zwijsen A., van Leuven F., de Strooper B., Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proceedings of the National Academy of Sciences of the United States of America 1999 96 21 11872 11877 2-s2.0-13044278313 10.1073/pnas.96.21.11872 (Pubitemid 29502825)
61. Burton C. R., Meredith J. E., Barten D. M., Goldstein M. E., Krause C. M., Kieras C. J., Sisk L., Iben L. G., Polson C., Thompson M. W., Lin X.-A., Corsa J., Fiedler T., Pierdomenico M., Cao Y., Roach A. H., Cantone J. L., Ford M. J., Drexler D. M., Olson R. E., Yang M. G., Bergstrom C. P., McElhone K. E., Bronson J. J., Macor J. E., Blat Y., Grafstrom R. H., Stern A. M., Seiffert D. A., Zaczek R., Albright C. F., Toyn J. H., The amyloid- β rise and γ -secretase inhibitor potency depend on the level of substrate expression. The Journal of Biological Chemistry 2008 283 34 22992 23003 2-s2.0-53149091309 10.1074/jbc.M804175200
62. Sankaranarayanan S., Price E. A., Wu G., Crouthamel M.-C., Shi X.-P., Tugusheva K., Tyler K. X., Kahana J., Ellis J., Jin L., Steele T., Stachel S., Coburn C., Simon A. J., In vivo β -secretase 1 inhibition leads to brain A β lowering and increased α -secretase processing of amyloid precursor protein without effect on neuregulin-1. Journal of Pharmacology and Experimental Therapeutics 2008 324 3 957 969 2-s2.0-40849083795 10.1124/jpet.107.130039 (Pubitemid 351397853)
63. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., LaFerla F. M., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. Neuron 2003 39 3 409 421 2-s2.0-0042697305 10.1016/S0896-6273(03)00434-3 (Pubitemid 36937044)
64. Lanz T. A., Schachter J. B., Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid- β from wild-type rodent brain. Journal of Neuroscience Methods 2006 157 1 71 81 2-s2.0-33748191750 10.1016/j.jneumeth.2006.03.023 (Pubitemid 44308360)
65. Toyn J. H., Lin X.-A., Thompson M. W., Guss V., Meredith J. E. Jr., Sankaranarayanan S., Barrezueta N., Corradi J., Majumdar A., Small D. L., Hansard M., Lanthorn T., Westphal R. S., Albright C. F., Viable mouse gene ablations that robustly alter brain A β levels are rare. BMC Neuroscience 2010 11, article 143 2-s2.0-78049386104 10.1186/1471-2202-11-143
66. Klafki H.-W., Wiltfang J., Staufenbiel M., Electrophoretic separation of β A4 peptides (1-40) and (1-42). Analytical Biochemistry 1996 237 1 24 29 2-s2.0-0029665851 10.1006/abio.1996.0195 (Pubitemid 26155625)
67. Kopan R., Schroeter E. H., Weintraub H., Nye J. S., Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proceedings of the National Academy of Sciences of the United States of America 1996 93 4 1683 1688 2-s2.0-0030003538 10.1073/pnas.93.4.1683 (Pubitemid 26075185)
68. Blat Y., Meredith J. E., Wang Q., Bradley J. D., Thompson L. A., Olson R. E., Stern A. M., Seiffert D., Mutations at the P1′ position of Notch1 decrease intracellular domain stability rather than cleavage by γ -secretase. Biochemical and Biophysical Research Communications 2002 299 4 569 573 2-s2.0-0036882124 10.1016/S0006-291X(02)02705-5 (Pubitemid 36034583)
69. Dayneka N. L., Garg V., Jusko W. J., Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics 1993 21 4 457 478 2-s2.0-0027769745 10.1007/BF01061691 (Pubitemid 24025269)
70. Mahmood I., Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Advanced Drug Delivery Reviews 2007 59 11 1177 1192 2-s2.0-35349016814 10.1016/j.addr.2007.05. 015 (Pubitemid 47615206)
71. Mordenti J., Chappell W., The use of interspecies scaling in toxicokinetics. Toxicokinetics and Drug Development 1989 New York, NY, USA Pergamon Press 42 96
72. Goodwin B., Hodgson E., Liddle C., The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Molecular Pharmacology 1999 56 6 1529 1539
73. Li W., A fast clustering algorithm for analyzing highly similar compounds of very large libraries. Journal of Chemical Information and Modeling 2006 46 5 1919 1923 2-s2.0-33750341686 10.1021/ci0600859 (Pubitemid 44625963)
74. Bustamante H. A., Rivera-Diccter A., Cavieres V. A., Turnover of C99 is controlled by a crosstalk between ERAD and ubiquitin-independent lysosomal degredation in human neuroglioma cells. PLoS ONE 2013 8 12, article e83096 10.1371/journal.pone.0083096
75. Borghys H., Tuefferd M., van Broeck B., Clessens E., Dillen L., Cools W., Vinken P., Straetemans R., De Ridder F., Gijsen H., Mercken M., A canine model to evaluate efficacy and safety of γ -secretase inhibitors and modulators. Journal of Alzheimer's Disease 2012 28 4 809 822 2-s2.0-84858059332 10.3233/JAD-2011-111475
76. Qin J., Zhou W., Huang X., Dhondi P., Palani A., Aslanian R., Zhu Z., Greenlee W., Cohen-Williams M., Jones N., Hyde L., Zhang L., Discovery of a potent pyrazolopyridine series of γ -secretase modulators. ACS Medicinal Chemistry Letters 2011 2 6 471 476 2-s2.0-79959223785 10.1021/ml2000438
77. Page R. M., Baumann K., Tomioka M., Pérez-Revuelta B. I., Fukumori A., Jacobsen H., Flohr A., Luebbers T., Ozmen L., Steiner H., Haass C., Generation of A β 38 and A β 42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and γ -secretase modulation. The Journal of Biological Chemistry 2008 283 2 677 683 2-s2.0-38149013121 10.1074/jbc.M708754200
78. Kretner B., Fukumori A., Gutsmiedl A., Page R. M., Luebbers T., Galley G., Baumann K., Haass C., Steiner H., Attenuated A β 42 responses to low potency γ -secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. The Journal of Biological Chemistry 2011 286 17 15240 15251 2-s2.0-79955426777 10.1074/jbc.M110.213587
79. Sinz M. W., Pregnane X receptor: "prediction and attenuation of human CYP3A4 enzyme induction and drug-drug interactions'. Annual Reports in Medicinal Chemistry 2008 43 405 418
80. Gijsen H. J. M., Mercken M., γ -Secretase modulators: can we combine potency with safety? International Journal of Alzheimer's Disease 2012 2012 10 2-s2.0-84872154160 10.1155/2012/295207 295207